- Home
- IMTE vs VIVS Comparison
IMTE vs VIVS Comparison
Compare IMTE & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTE
- VIVS
- Stock Information
- Founded
- IMTE 2008
- VIVS 2007
- Country
- IMTE Malaysia
- VIVS United States
- Employees
- IMTE N/A
- VIVS N/A
- Industry
- IMTE Consumer Electronics/Appliances
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMTE Consumer Staples
- VIVS Health Care
- Exchange
- IMTE Nasdaq
- VIVS Nasdaq
- Market Cap
- IMTE 4.1M
- VIVS 4.2M
- IPO Year
- IMTE N/A
- VIVS N/A
- Fundamental
- Price
- IMTE $0.99
- VIVS $1.45
- Analyst Decision
- IMTE
- VIVS
- Analyst Count
- IMTE 0
- VIVS 0
- Target Price
- IMTE N/A
- VIVS N/A
- AVG Volume (30 Days)
- IMTE 10.6K
- VIVS 64.3K
- Earning Date
- IMTE 07-07-2025
- VIVS 07-07-2025
- Dividend Yield
- IMTE N/A
- VIVS N/A
- EPS Growth
- IMTE N/A
- VIVS N/A
- EPS
- IMTE N/A
- VIVS N/A
- Revenue
- IMTE $123,337.00
- VIVS $144,000.00
- Revenue This Year
- IMTE N/A
- VIVS $42.38
- Revenue Next Year
- IMTE N/A
- VIVS $15.42
- P/E Ratio
- IMTE N/A
- VIVS N/A
- Revenue Growth
- IMTE 4.75
- VIVS 32.11
- 52 Week Low
- IMTE $0.51
- VIVS $1.41
- 52 Week High
- IMTE $3.17
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- IMTE 34.23
- VIVS N/A
- Support Level
- IMTE $0.87
- VIVS N/A
- Resistance Level
- IMTE $1.02
- VIVS N/A
- Average True Range (ATR)
- IMTE 0.05
- VIVS 0.00
- MACD
- IMTE -0.01
- VIVS 0.00
- Stochastic Oscillator
- IMTE 41.93
- VIVS 0.00
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.